209 related articles for article (PubMed ID: 30060176)
1. Urate-lowering treatment and risk of total joint replacement in patients with gout.
Kuo CF; Chou IJ; See LC; Chen JS; Yu KH; Luo SF; Hsieh AH; Zhang W; Doherty M
Rheumatology (Oxford); 2018 Dec; 57(12):2129-2139. PubMed ID: 30060176
[TBL] [Abstract][Full Text] [Related]
2. Associations between urate-lowering therapy and the risk of type 2 diabetes mellitus.
Chang HW; Lin YW; Lin MH; Lan YC; Wang RY
PLoS One; 2019; 14(1):e0210085. PubMed ID: 30615649
[TBL] [Abstract][Full Text] [Related]
3. Urate-lowering therapy may mitigate the risks of hospitalized stroke and mortality in patients with gout.
Yen FS; Hsu CC; Li HL; Wei JC; Hwu CM
PLoS One; 2020; 15(6):e0234909. PubMed ID: 32574194
[TBL] [Abstract][Full Text] [Related]
4. Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: a population-based cohort study.
Roughley M; Sultan AA; Clarson L; Muller S; Whittle R; Belcher J; Mallen CD; Roddy E
Arthritis Res Ther; 2018 Oct; 20(1):243. PubMed ID: 30376864
[TBL] [Abstract][Full Text] [Related]
5. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study.
Kuo CF; Grainge MJ; Mallen C; Zhang W; Doherty M
Ann Rheum Dis; 2015 Apr; 74(4):661-7. PubMed ID: 24431399
[TBL] [Abstract][Full Text] [Related]
6. Cohort study investigating gout flares and management in UK general practice.
Finnikin S; Mallen CD; Roddy E
BMC Prim Care; 2023 Nov; 24(1):246. PubMed ID: 37993770
[TBL] [Abstract][Full Text] [Related]
7. Treat-to-target urate-lowering therapy and hospitalizations for gout: results from a nationwide cohort study in England.
Russell MD; Roddy E; Rutherford AI; Ellis B; Norton S; Douiri A; Gulliford MC; Cope AP; Galloway JB
Rheumatology (Oxford); 2023 Jul; 62(7):2426-2434. PubMed ID: 36355461
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology and management of gout in Taiwan: a nationwide population study.
Kuo CF; Grainge MJ; See LC; Yu KH; Luo SF; Zhang W; Doherty M
Arthritis Res Ther; 2015 Jan; 17(1):13. PubMed ID: 25612613
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare.
Janssen CA; Oude Voshaar MAH; Ten Klooster PM; Vonkeman HE; van de Laar MAFJ
Clin Rheumatol; 2019 Aug; 38(8):2233-2239. PubMed ID: 31030363
[TBL] [Abstract][Full Text] [Related]
10. Patient and clinical characteristics associated with gout flares in an integrated healthcare system.
Rashid N; Levy GD; Wu YL; Zheng C; Koblick R; Cheetham TC
Rheumatol Int; 2015 Nov; 35(11):1799-807. PubMed ID: 25991397
[TBL] [Abstract][Full Text] [Related]
11. A joint effort over a period of time: factors affecting use of urate-lowering therapy for long-term treatment of gout.
Richardson JC; Liddle J; Mallen CD; Roddy E; Hider S; Prinjha S; Ziebland S
BMC Musculoskelet Disord; 2016 Jun; 17():249. PubMed ID: 27267878
[TBL] [Abstract][Full Text] [Related]
12. Gout, urate-lowering therapy, and uric acid levels among adults in the United States.
Juraschek SP; Kovell LC; Miller ER; Gelber AC
Arthritis Care Res (Hoboken); 2015 Apr; 67(4):588-92. PubMed ID: 25201123
[TBL] [Abstract][Full Text] [Related]
13. Adherence and persistence to urate-lowering therapies in the Irish setting.
McGowan B; Bennett K; Silke C; Whelan B
Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
[TBL] [Abstract][Full Text] [Related]
14. Regular pre-admission urate-lowering therapy and serum urate testing are associated with a shorter hospital length of stay in people with gout: A nation-wide population-based cohort study.
Jatuworapruk K; Grainger R; Dalbeth N; Taylor WJ
Int J Rheum Dis; 2022 Feb; 25(2):154-162. PubMed ID: 34796661
[TBL] [Abstract][Full Text] [Related]
15. Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study.
Pisaniello HL; Lester S; Gonzalez-Chica D; Stocks N; Longo M; Sharplin GR; Dal Grande E; Gill TK; Whittle SL; Hill CL
Arthritis Res Ther; 2018 Jul; 20(1):143. PubMed ID: 29996922
[TBL] [Abstract][Full Text] [Related]
16. Urate-lowering Therapy and Chronic Kidney Disease Development in Patients with Gout.
Yen FS; Wei JC; Chang CL; Yang CC; Hsu CC; Hwu CM
Int J Med Sci; 2021; 18(12):2599-2606. PubMed ID: 34104091
[No Abstract] [Full Text] [Related]
17. Dyslipidemia, Alcohol Consumption, and Obesity as Main Factors Associated With Poor Control of Urate Levels in Patients Receiving Urate-Lowering Therapy.
Latourte A; Bardin T; Clerson P; Ea HK; Flipo RM; Richette P
Arthritis Care Res (Hoboken); 2018 Jun; 70(6):918-924. PubMed ID: 28834411
[TBL] [Abstract][Full Text] [Related]
18. Lowering Serum Urate With Urate-Lowering Therapy to Target and Incident Fracture Among People With Gout.
Wei J; Choi HK; Dalbeth N; Lane NE; Wu J; Lyu H; Zeng C; Lei G; Zhang Y
Arthritis Rheumatol; 2023 Aug; 75(8):1456-1465. PubMed ID: 36940260
[TBL] [Abstract][Full Text] [Related]
19. Effect of Urate-Lowering Therapy on All-Cause and Cardiovascular Mortality in Hyperuricemic Patients without Gout: A Case-Matched Cohort Study.
Chen JH; Lan JL; Cheng CF; Liang WM; Lin HY; Tsay GJ; Yeh WT; Pan WH
PLoS One; 2015; 10(12):e0145193. PubMed ID: 26683302
[TBL] [Abstract][Full Text] [Related]
20. Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia.
Levy GD; Rashid N; Niu F; Cheetham TC
J Rheumatol; 2014 May; 41(5):955-62. PubMed ID: 24692523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
